My expertise is in both oncology and hematology. Although the majority of my time is spent in the laboratory, I enjoy taking care of patients at Children's Hospital. My research has given me a broad clinical approach that helps me diagnose and treat the rare child who is "off the grid," particularly when there is an oncology/hematology problem that has gone unsolved. I also specialize in hematopoietic stem cell transplant (bone marrow transplant) and use my expertise in transplant to help treat patients with autoimmune diseases.
My clinical research is focused on better understanding diseases of white blood cells in children, in particular leukemia and a rare disorder called autoimmune lymphoproliferative syndrome (ALPS). I focus on creating novel therapeutics for leukemia and ALPS, and have been successful in bringing drugs from the bench to the bedside to treat children with these conditions.
I am the principal investigator for a clinical trial that is using the mTOR inhibitor rapamycin (sirolimus) in children with multiple medical conditions. mTOR is a key protein in a pathway that regulates cell activities including growth and survival. The autoimmune conditions we are looking at in this trial include ALPS, chronic Immune Thrombocytopenic Purpura (ITP, a blood disorder that involves the immune and blood clotting systems) and lupus (a chronic, inflammatory autoimmune disorder.) I also run an ongoing multi-institutional trial to diagnose and better characterize children with ALPS.
My basic science research focuses on the same two areas: leukemia and autoimmune diseases. My first area of interest is the signal transduction pathways and inhibitors of those pathways in acute lymphoblastic leukemia (ALL). My lab targets the mTOR signaling pathway with novel therapeutics. We use xenograft (tissue grafts from one species to another) models to study the efficacy and action of those therapeutic agents directly on leukemia cells removed from children. This work has led to a number of nationwide Children's Oncology Group-initiated clinical trials that test mTOR inhibitors in patients with ALL.
The other major area of basic research in my lab centers on investigating novel therapeutics and signaling pathways in autoimmune diseases, particularly ALPS. Using preclinical models, I am targeting both mTOR and Notch cell signaling as treatment approaches for patients with ALPS and other autoimmune diseases. I am also interested in understanding lymphocyte biology in ALPS and other autoimmune diseases.
I became interested in ALPS as a doctor in training. We had patients with this disorder and couldn't figure out what it was or how to treat it. Now I run the one of the biggest clinics in the world for ALPS. Because of our new treatments, patients are doing better than ever before.
At Children's Hospital, we are somewhat unique in that we value and excel at both patient care and basic science and clinical science. We are able to put our full weight on all the pathways to help children with cancer and blood disorders.
- Education and Training
MD - Eastern Virginia Medical School, Norfolk, VA
Pediatrics - Children's National Medical Center, Washington, DC
Pediatric Hematology and Oncology - The Children's Hospital of Philadelphia, Philadelphia, PA
Postdoctoral Research Fellow in Pediatric Hematology and Oncology - The Children's Hospital of Philadelphia, Philadelphia, PA
American Board of PediatricsAmerican Board of Pediatrics/Hematology-Oncology
- Titles and Academic Titles
Assistant Professor of Pediatrics, Perelman School of Medicine at the University of Pennsylvania
- Departments and Services
- Research Interests
Novel therapeutics for leukemia and the Autoimmune Lymphoproliferative Syndrome
Teachey DT: Lymphoproliferative Disorders, Acute Myeloid Leukemia, Wilms Tumor, Pallor. In: The 5-Minute Pediatric Consult. M. William Schwartz (eds.). Lippincott Williams and Wilkins Publisher, Hagerstown, MD, 6th edition. Page: 22-3, 518-9, 614-5, 950-1, June 2012 Notes: *Four separate chapters.
Teachey DT: Leukocytosis. In: Schwartz's Clinical Handbook of Pediatrics. Joseph J. Zorc (eds.). Lippincott Williams and Wilkins Publisher, Hagerstown, MD, 5th edition. Page: 517-26, April 2012.
Teachey DT: Leukopenia. In: Schwartz's Clinical Handbook in Pediatrics. Joseph J. Zorc (eds.). Lippincott Williams and Wilkins Publisher, Hagerstown, MD, 5th edition. Page: 527-35, April 2012.
Teachey DT: Lymphoproliferative Disorders, Myelodysplastic Syndromes, and Myeloproliferative Disorders. In: Manual of Pediatric Hematology/Oncology Philip Lanzkowsky (eds.). Academic Press, Elsevier, St. Louis, MO, 5th Edition, Page: 472-517, October 2010.
Teachey DT, Rheingold S, Bunin N. Germ cell tumors. In: Brodeur G, Manno C, editors. Requisites in pediatrics: hematology and oncology. 1st ed. Philadelphia: Elsevier Health Sciences-Mosby Publisher; 2008.
Teachey DT, Bunin N. Hematopoietic stem cell transplantation. In: Haelfer M, Chambers J, editors. Requisites in pediatrics: critical care medicine. 1st ed. Philadelphia: Elsevier Health Sciences-Mosby Publisher; 2008.
Teachey DT, Manno C. Hematologic manifestations of systemic disease. In: Brodeur G, Manno C, editors. Requisites in pediatrics: hematology and oncology. 1st ed. Philadelphia: Elsevier Health Sciences-Mosby Publisher; 2008.
Teachey DT. Pallor. In: Schwartz MW, Bell LM, editors. The 5-minute pediatric consult. 5th ed. Hagerstown (MD): Lippincott Williams & Wilkins Publisher; 2008.
Teachey DT. Wilms Tumor. In: Schwartz WM, Bell LM Jr., editors. The 5-minute pediatric consult. 5th ed. Hagerstown (MD): Lippincott Williams & Wilkins Publisher; 2008.
Teachey DT. Acute myelogenous leukemia. In: Schwartz WM, Bell LM Jr., editors. The 5-minute pediatric consult. 5th ed. Hagerstown (MD): Lippincott Williams & Wilkins Publisher; 2008.
Porter DL, Lacey SF, Hwang W, Shaw P, Frey N, Chew A, Chen F, Kalos M, Gonzalez V, Marcucci K, Maude SL, Melenhorst J, Litchman M, Teachey DT, Shen A, Quintas-Cardamas A, Wood P, Levine BL, June CH, Grupp SA: Cytokine release syndrome (CRS) after chimeric antigen receptor (CAR) T cell therapy for relapsed/refractory (R/R) CLL. Blood 124(21): 1983, December 2014 Notes: American Society of Hematology. Annual Meeting Abstracts.
Liou A, Delgado-Martin C, Teachey DT, Hermiston M: The CXCR4/CXCL12 axis mediates chemotaxis, survival, and chemoresistance in T-cell acute lymphoblastic leukemia. Blood 124(20): 3629, December 2014 Notes: American Society of Hematology. Annual Meeting Abstracts.
Dolai S, Sia K, Robbins A, Zhong A, Heatley S, Vincent T, Hochgrafe F, Kurmasheva R, White D, Houghton PJ, Smith M, Teachey DT, Daly R, Raftery M, Lock RB: Targeted Cancer Therapy in High-Risk Pediatric Leukemia Using Global Phosphotyrosine Profiling. Blood 124(20): 969, December 2014 Notes: American Society of Hematology. Annual Meeting Abstracts.
Urtishak K, Li-San W, Teachey DT, Tasian SK, Barrett JS, Chen I, Atlas SR, Harvey RC, Heerema NA, Carroll AJ, Hunger SP, Willman SL, and Felix CA: PI3K/Akt/mTOR signaling is a significant druggable pathway in infant acute lymphoblastic leukemia (ALL). Blood 122: 1669, Nov 2013 Notes: American Society of Hematology Annual Meeting.
Teachey DT, Vincent T, Smith-Whitley, Lambert MP, Seif AE, Casper JT, and Grupp SA: Targeting mTOR signaling leads to complete and durable responses in children with multi-lineage autoimmune cytopenias, including ALPS, SLE, Evans, and CVID. Blood 122: 330, Nov 2013 Notes: American Society of Hematology Annual Meeting, Oral Platform Presentation.
Oshrine B, Li Y, Teachey DT, Heimall J, and Bunin NJ: Immunologic reconstitution following hematopoietic stem cell transplantation (HSCT) in children: comparison of T-cell depletion using the clinics system with unmanipulated bone marrow and umbilical cord blood. Pediatr Blood Cancer 60: 901, June 2013 Notes: American Society of Pediatric Hematology Oncology Annual Meeting.
Pulsipher M, Langholz B, Wall DA, Schultz KR, Bunin N, Carroll W, Raetz E, Gardner S, Goyal R, Gastier-Foster J, Borowitz M, Teachey D, and Grupp SA: Risk factors and timing of relapse after allogeneic transplantation in pediatric ALL: for whom and when should interventions be tested? Bone Marrow Transplantation Epub ahead of print, May 2015.
Maude SL, Dolai S, Delgado-Martin C, Vincent T, Robbins A, Selvanathan A, Ryan T, Hall J, Wood A, Tasian SK, Hunger S, Loh M, Mullighan C, Wood B, Hermiston M, Grupp SA, Lock RB, and Teachey DT: Efficacy of Jak/Stat pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia. Blood 125(11): 1759-67, March 2015.
Maude SL, Frey N, Shaw P, Aplenc R, Barrett D, Bunin NJ, Chew A, Gonzalez G, Zheng Z, Lacey SF, Mhanke Y, Melenhorts JJ, Rheingold SR, Shen A, Teachey DT, Levine B, June CH, Porter DL, and Grupp SA: Chimeric antigen receptor T cells for sustained remissions in leukemia. New Engl J Med 371(16): 1507-17, October 2014.
Jones CL, Bhatia T, Blum R, Wang J, Paugh SW, Wen X, Bourgeois W, Bitterman DS, Raetz EA, Morrison DJ, Teachey DT, Evans WE, Garabedian MJ, Carroll WL: Loss of TBL1XR1 Disrupts Glucocorticoid Receptor Recruitment to Chromatin and Results in Glucocorticoid Resistance in a B-Lymphoblastic Leukemia Model. J Biol Chem 289(30): 20502-15, Jul 2014.
Pulsipher MA, Langholz B, Wall D, Schultz K, Bunin N, Carroll WL, Raetz E, Gardner S, Gastier-Foster JM, Howrie D, Goyal RK, Douglas JG, Borowitz M, Barnes Y, Teachey DT, Taylor C, Grupp SA: The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase III COG/PBMTC trial. Blood 123(13): 2017-25, March 2014.
Oshrine BR, Li Y, Teachey DT, Heimall J, Barrett DM, Bunin N: Immunologic recovery in children after alternative donor allogeneic transplantation for hematologic malignancies: comparison of recipients of partially T cell-depleted peripheral blood stem cells and umbilical cord blood. Biol Blood Marrow Transplant 19(11): 1581-9, November 2013.
Chellapandian D, Rupali D, Zelly K, Wiener S, Zhao H, Teachey DT, and Nichols K: Treatment of Epstein Barr virus-induced hemophagocytic lymphohistiocytosis with rituximab-containing chemotherapeutic regimens. Br J Haematol 162(3): 376-82, August 2013.
Teachey DT, Rheingold SR, Maude SL, Zugmaier G, Barrett DM, Nichols KE, Suppa EK, Kalos M, Berg RA, Fitzgerald J, Aplenc R, Gore R, and Grupp SA: Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine directed therapy. Blood 121(26): 5154-7, June 2013.
Grupp SA, Kalos M, Barrett DM, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Levine B, and June CH: Induction of complete remission of ALL by chimeric antigen receptor-expressing T cells. N Engl J Med 368(16): 1509-18, April 2013.
Posters and Presentations
Maude SL, Dolai S, Delgado-Martin C, Hunger SP, Loh M, Mullighan CG, Hermiston M, Grupp SA, Lock R, and Teachey DT: Early T-cell precursor (ETP) acute lymphoblastic leukemia is characterized by aberrant activation of Jak/Stat pathway and profound responses to ruxolitinib in xenograft models. Pediatr Blood and Cancer 61(S2): 0-013, December 2014 Notes: International Society of Paediatric Oncology Annual Meeting. Oral abstract presentation.
Grupp SA, Maude SL, Shaw P, Aplenc R, Barrett DM, Callahan C, Chew A, Lacey SF, Levine B, Melenhorst J, Motley L, Rheingold SR, Shen A, Teachey DT, Wood P, Porter DL, and June CH: T cell engineered with a chimeric antigen receptor (CAR) targeting CD19 (CTL019) have long term persistence and induce durable remissions in children with relapsed, refractory ALL. Blood 2104(20): 380, December 2014 Notes: American Society of Hematology. Annual Meeting Abstracts. Oral Platform Presentation.
Maude SL, Dolai S, Delagdo-Martine C, Vincent T, Robbins A, Selvanathan A, Ryan T, Hunger SP, Loh ML, Mullighan CG, Wood BL, Hermiston M, Grupp SA, Lock RB, and Teachey DT: Targeting the Jak/Stat signaling pathway is highly effective in xenograft models of early T cell precursor (ETP) acute lymphoblastic leukemia (ALL). Cancer Research Page: 997, May 2014 Notes: American Association for Cancer Research (AACR) Annual Meeting. Oral Platform Presentation.
Tasian SK, Li Y, Ryan T, Vincent T, Teachey DT, Loh ML, Hunger SP, Carroll M, and Grupp SA: In Vivo Efficacy of PI3K Pathway Signaling Inhibition for Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia. Blood 112: 2672, November 2013 Notes: American Society of Hematology Annual Meeting.
Jones CL, Bhatia T, Wang J, Bourgeois W, Danielle BS, Raetz EA, Morrison DJ, Teachey DT, Michael G, and Carroll WL: Deletions in TBL1XR1 results in glucocorticoid resistance by decreasing glucocorticoid signaling in childhood B-lymphoblastic leukemia. Blood 122: 602, Nov 2013 Notes: American Society of Hematology Annual Meeting Abstracts, Oral Platform Presentation.
Grupp SA, Frey NV, Aplenc R, Barrett DM, Chew A, Kalos M, Levine BL, Litchman M, Maude SL, Rheingold SR, Shen A, Strait C, Teachey DT, Wood PA, Porter D, and June CH: T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 (CTL019) produce significant in vivo proliferation, complete responses and long-term persistence without gvhd in children and adults with relapsed, refractory ALL. Blood 122: 67, Nov 2013 Notes: American Society of Hematology Annual Meeting, Oral platform presentation.
Barrett DM, Kalos M, Teachey DT, Levine B, Rheingold SR, Aplenc R, Porter DL, June CH, and Grupp SA: CD19-targeted chimeric antigen receptor (CAR)-modified T (CTL019) cells in pediatric ALL: immune activation syndromes and durable response. Pediatr Blood Cancer. American Society of Pediatric Hematology Oncology Annual Meeting, Oral Platform presentation, 60: 403, June 2013.
Grupp SA, Kalos M, Barrett DM, Teachey DT, Levin B, Milone M, Porter DL, and June CH: Use of CD19-targeted chimeric antigen receptor-modified T (CART19) cells in ALL and CLL produce transient cyokine release syndrome (CRS), macrophage activation syndrome (MAS) and durable response. Cancer Research Page: 4574, April 2013 Notes: AACR Annual Meeting, Oral Platform presentation.
"Using xenograft models of high risk ALL subtypes to develop novel targeted therapies," iBFM Annual Meeting, Budapest Hungary, May 2015.
"Targeting Jak/Stat in T-ALL," The Fifteenth International Childhood Acute Lymphoblastic Leukemia Workshop, Ponte di Legno Group Meeting, Sonoma, CA, December 2014.
"Biology and Management of Hypercytokinemia Following Novel T-cell Engaging Therapies," Midyear Joint Meeting of International Cytokine Society, Kiel Germany, May 2014.
"Proactive Surveillance in ALPS Patients", CIS Annual Meeting, Baltimore, MD, April 2014.
"Biology and Management of Hypercytokinemia Following T-cell Engaging Novel Therapies," Annual Meeting of the Histiocyte Society, Washington DC, October 2013.
"AALL1231," Children's Oncology Group Annual Meeting, Dallas TX, September 2013.
"Repurposing drugs for childhood disease," Cures Within Reach Midwest Bioscience Event, Chicago, IL, May 2013.
"Autoimmune Lymphoproliferative Syndrome," Clinical Immunology Society Annual Meeting, Miami FL, April 2013.
"Chimeric Antigen Receptor T cells for Acute Lymphoblastic Leukemia," Children's Oncology Group Spring Working Meeting, Minneapolis, MN, March 2013.
"Novel Therapies for Relapsed T-ALL," Children's Oncology Group Spring Working Meeting, Minneapolis, MN, March 2013.
"Targeted Therapy for ALL and ALPS," Vancouver, Canada, March 2013.
- Awards and Honors
2013, The 2013 Golan and Christie Advancement Award for Saving Lives Through Rediscovery Research, Cures Within Reach
2011, John Morgan Society, University of Pennsylvania
2010., The Lady Barbara Colyton Autoimmune Research Award, University of Pennsylvania School of Medicine Award of Excellence
2007, Hoag Award in Pediatric Translational Research
2006, Conquer Cancer Foundation of the American Society of Clinical Oncology Career Development Award
2006, Foerderer-Murray Award
2006, United States Immunodeficiency Research Award
2005, Joseph Stokes Jr. Research Institute, Clinical Science Research Award
2005, American Society of Pediatric Hematology Oncology Young Investigator Award
2005, Conquer Cancer Foundation of the American Society of Clinical Oncology Young Investigator Award
2005, Judy S. Finkelstein Memorial Award in Immunology Research
2004, Charles E Culpepper Biomedical Pilot Initiative Award
2004, National Institute of Health Loan Repayment Award (with renewal in 2006, 2008, and 2010)
1998, Alpha Omega Alpha, National Medical Honor Society, Junior Year Elect
1993, Graduated Magna cum laude with Honors - Virginia Commonwealth University, Richmond, VA
- Editorial and Academic Positions
Academic and Institutional Committees
2013-present, HLH multi-disciplinary committee
- 2014-present, Section Leader
2012-present, Oncology Tumor Board and Journal Club Weekly, coordinator
2012-present, CCCR Biobank Scientific Review Committee, reviewer
2011-present, Colyton Selection Committee
2011-present, Leukemia and Lymphoma Committee
2010-present, IRB, Executive Committee
2010-present, Hematology and Oncology Fellowship Committee
2008-present, Pediatric Protocol Review Committee
2008-present, IRB, reviewer
2005-present, Blood and Marrow Transplant Steering Committee
Memberships in Professional Organizations
2013-present, St. Baldrick's Foundation Grant Review
2013-present, NIH. DT (Developmental Therapeutics) Study Section, ad hoc reviewer
2005-present, Children's Oncology Group
- 2015-present, Vice Chair (Biology) ALL Disease Committee
- 2012-present, ALL Disease Committee
- 2012-present, AALL1231 Study Chair
- 2011-present, ADVL0921 Vice Chair
- 2011-present, AALL1131 Study Committee
- 2011-present, ADVL1114 Vice Chair
- 2010-present, T-ALL Task Force; Section Leader on New Agents
- 2010-present, HSCT Discipline Steering Committee
- 2009-present, ADVL0919 Vice Chair
- 2009-present, ALL-DVL/Relapse Committee
- 2008-present, ADVL0812 Study Committee
- 2005-present, ASCT0431 Study Committee
2003-present, American Society of Pediatric Hematology-Oncology
2003-present, American Society of Hematology
2003-present, American Society of Clinical Oncology
- Awards and Honors